A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
This study is currently recruiting participants.
Verified August 2017 by Genentech, Inc.
First Posted: February 15, 2011
Last Update Posted: August 23, 2017
Information provided by (Responsible Party):